Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Blood Cancer Drugs Market Expected To Grow In Terms Of Size?

Over the past few years, the market size of blood cancer drugs has seen substantial growth. It is forecasted to rise from $74.69 billion in 2024 to $79.6 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.6%. The significant growth seen in the historic period can be credited to improvements in research and development, an aging demographic, heightening awareness and earlier diagnoses, and regulatory approvals.

The market for blood cancer drugs is predicted to experience robust growth in the upcoming years. The market is due to increase to “$104.37 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%. The predicted growth over this period can be credited to the increase in disease occurrence, developing markets, as well as supportive care. Key trends projected to shape this period include stake in research and development, combination therapies, biomarker discovery, improvements in immunotherapy, and individualized medicine.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

Which Growth Drivers Are Shaping The Blood Cancer Drugs Market Outlook?

Global growth in blood cancer drugs market is being propelled by the rising mortality rates and intensifying prevalence of global blood cancer instances. Various kinds of blood cancers, including lymphoma, leukemia, myeloma, among others, have diverse risk factors; some can be regulated or averted through drug therapies, while some could be fatal. For instance, the Bristol-Myers Squibb Company reported in November 2022 that they anticipate over 1.85 million new cases of blood cancer worldwide by 2040, with 918,872 cases of lymphoma, 656,345 cases of leukemia, and 275,047 cases of myeloma. Additionally, they predict approximately 1,100,000 deaths worldwide due to blood cancer by 2040. The escalating mortality rates and ascending instances of blood cancer worldwide are propelling the market for blood cancer drugs.

How Is The Blood Cancer Drugs Market Segmented Across Key Categories?

The blood cancer drugs market covered in this report is segmented –

1) By Blood Cancer Type: Leukemia, Lymphoma

2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs

3) By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic

Subsegments:

1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia

2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma

What Key Trends Are Driving Growth In The Blood Cancer Drugs Market?

To gain a competitive advantage in the blood cancer drugs market, leading corporations are focusing on the development of new drugs and attaining FDA approval. The United States Food and Drug Administration (FDA) provides FDA approval as official permission for a pharmaceutical product to be legally marketed and sold in the United States. For example, in March 2024, USA’s pharmaceutical company, Bristol Myers Squibb, secured FDA approval for it’s first and exclusive CAR T-cell therapy for adults suffering from persistent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This expedited approval permits its application in patients who have previously undergone at least two treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphocytic 2 inhibitor. The TRANSCEND CLL 004 trial indicates that Breyanzi showed a 20% complete response rate, with responders attaining a median duration of response of 35.3 months.

Which Companies Are Contributing Significantly To The Blood Cancer Drugs Market Growth?

Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Which Region Dominates The Blood Cancer Drugs Market Today?

North America was the largest region in the blood cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=2587&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model